Alphabet-founded biotech Calico Life Sciences has struck an exclusive licensing agreement with Chinese drugmaker Mabwell (SHA ...

Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

Researchers evaluated the efficacy and safety of icotrokinra for treating plaque psoriasis affecting the scalp, genital, and/or hand/foot areas.

Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet ...

Water fasting can lead to fast weight loss. But it also comes with real risks: inflammation, nutrient deficiencies, muscle ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Procalcitonin emerged as a strong diagnostic marker that may boost early SAP detection when combined with predictive models.

Researchers have found in a recent analysis reveals IL-17 inhibitors significantly increase the risk of Candida infections ...

Premal Thaker, MD, MS, discusses important implications and takeaways of the phase 1/2 OVATION study of IMMN-1 in addition to chemotherapy for the treatment of newly diagnosed epithelial ovarian ...

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients ...